IOTA简单规则与O-RADS联合CA125、HE4及恶性肿瘤风险算法鉴别卵巢附件良恶性肿块的诊断效能
该回顾性研究纳入2021年9月至2022年2月手术病理证实的1179个卵巢附件肿块,比较IOTA简单规则(IOTA SR)与O-RADS及联合CA125、HE4、ROMA的诊断效能。全体女性中O-RADS敏感度显著高于IOTA SR(95.77% vs 87.32%,P<0.001),AUC无显著差异;绝经前女性O-RADS的AUC显著高于其他策略;绝经后女性IOTA SR+ROMA的AUC显著高于其他策略。
要点
- 绝经前女性O-RADS的AUC显著高于其他策略,敏感度93.33%、特异度84.74%、准确率85.59%。
- 绝经后女性IOTA SR+ROMA的AUC显著高于其他策略,敏感度85.37%、特异度93.88%、准确率90.00%。
- 全体女性O-RADS敏感度显著高于IOTA SR(95.77% vs 87.32%,P<0.001),AUC无显著差异。
核心结论
- IOTA SR或O-RADS单独应用在全体女性中均有较高诊断价值,O-RADS敏感度高于IOTA SR;绝经前女性O-RADS诊断价值最高,绝经后女性IOTA SR优于O-RADS且IOTA SR+ROMA诊断价值最高。
研究设计与样本
- 回顾性研究,纳入2021年9月至2022年2月手术病理证实的1179个卵巢附件肿块,以手术病理为参考标准,计算AUC、敏感度、特异度评价IOTA SR、O-RADS及其联合CA125、HE4、ROMA的诊断效能。
诊断标准与关键数值
- 全体女性:IOTA SR的AUC为0.879,O-RADS的AUC为0.889,两者比较P=0.361。
- 全体女性:O-RADS敏感度95.77%,IOTA SR敏感度87.32%,O-RADS显著更高(P<0.001)。
- 绝经前女性:O-RADS的AUC显著高于其他诊断策略(均P<0.05),敏感度93.33%、特异度84.74%、准确率85.59%。
- 绝经后女性:IOTA SR+ROMA的AUC显著高于其他诊断策略(均P<0.05),敏感度85.37%、特异度93.88%、准确率90.00%。
临床应用与阅片要点
- 绝经前女性可优先参考O-RADS,其AUC显著高于其他策略。
- 绝经后女性可参考IOTA SR+ROMA,其AUC显著高于其他策略。
- 全体女性中O-RADS敏感度显著高于IOTA SR(95.77% vs 87.32%,P<0.001)。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the diagnostic performance of International Ovarian Tumour Analysis Simple Rules (IOTA SR) and Ovarian-Adnexal Reporting and Data System (O-RADS), and to analyse whether combining IOTA SR and O-RADS with the biomarkers cancer antigen 125 (CA125), human epididymis protein 4 (HE4), and risk of malignancy algorithm (ROMA) further improves diagnostic performance in women with different menopause status.
METHODS: This study retrospectively included patients with ovarian adnexal masses confirmed by surgical pathology between September 2021 and February 2022. The area under the curve (AUC), sensitivity, and specificity were calculated to evaluate the diagnostic efficacy of IOTA SR, O-RADS, and their combination with CA125, HE4, and ROMA.
RESULTS: This study included 1,179 ovarian adnexal masses. In all women, the AUC of IOTA SR was comparable to O-RADS (0.879 vs. 0.889, P = 0.361), and O-RADS had a significantly higher sensitivity than IOTA SR (95.77 % vs. 87.32 %, P < 0.001). In premenopausal women, O-RADS had a significantly higher AUC than other diagnostic strategies (all P < 0.05), and the sensitivity, specificity, and accuracy were 93.33 %, 84.74 %, and 85.59 %, respectively. In postmenopausal women, IOTA SR + ROMA had a significantly higher AUC than other diagnostic strategies (all P < 0.05), and the sensitivity, specificity, and accuracy were 85.37 %, 93.88 %, and 90.00 %, respectively.
CONCLUSIONS: Our study supports the high diagnostic value of IOTA SR or O-RADS alone in all women, and O-RADS was more sensitive than IOTA SR. In premenopausal women, O-RADS had the highest diagnostic value. In postmenopausal women, IOTA SR outperformed O-RADS, and IOTA SR + ROMA had the highest diagnostic value.
引用
- Yang, Ju, Huang, et al. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses. Eur J Radiol. 2023. PMID: 37418798. doi:10.1016/j.ejrad.2023.110926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。